Royal Marsden NHS Foundation Trust (GB)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
122
Publications
1335
Citations
121106
i10-index
540
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Combined Nivolumab and Ipilimumab or Monotherapy i... | 2015 | 7548 |
Improved Survival with Vemurafenib in Melanoma wit... | 2011 | 7466 |
Intratumor Heterogeneity and Branched Evolution Re... | 2012 | 7246 |
Pembrolizumab versus Ipilimumab in Advanced Melano... | 2015 | 5365 |
Nivolumab versus Everolimus in Advanced Renal-Cell... | 2015 | 5356 |
Overall Survival with Combined Nivolumab and Ipili... | 2017 | 4981 |
Five-Year Survival with Combined Nivolumab and Ipi... | 2019 | 3146 |
Nivolumab versus chemotherapy in patients with adv... | 2015 | 2546 |
Avelumab plus Axitinib versus Sunitinib for Advanc... | 2019 | 2149 |
Management of toxicities from immunotherapy: ESMO ... | 2017 | 2145 |
James Larkin is a researcher with 1335 publications and 121106 citations. They are affiliated with Royal Marsden NHS Foundation Trust. Their research focuses on Biology, Medicine, Internal medicine and other areas. With an h-index of 122, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from James Larkin and 250M+ other papers.
Citations per publication by year